ProShares UltraShort Nasdaq Biotech (BIS)

7.96 +0.20  +2.58% NASDAQ Jul 13, 20:00 Delayed 2m USD
View Full Chart
Price Chart

Key Stats

Net Asset Value 7.968
Discount or Premium to NAV -0.10%
Turnover Ratio --
1 Year Fund Level Flows 1.838M

Performance & Returns

  Total Return (Price) Total Return (NAV) Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M -14.13% -13.99% -- --
3M -34.97% -34.96% -- --
6M -41.93% -41.87% -- --
YTD -40.50% -40.48% -- --
1Y -55.86% -55.75% -- --
3Y -29.54% -29.54% -- --
5Y -21.38% -21.35% -- --
10Y -40.58% -40.57% -- --
15Y -- -- -- --
20Y -- -- -- --
As of July 13, 2020. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 293.0% 293.0% 0.00%
Stock -193.0% 0.00% 193.0%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of June 30, 2020

Region Exposure

Americas 100.0%
North America 100.0%
Latin America 0.00%
Greater Europe 0.00%
United Kingdom 0.00%
Europe Developed 0.00%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.00%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.00%
Market Classification
% Developed Markets 100.0%
% Emerging Markets 0.00%
As of June 30, 2020. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 0.00%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of June 30, 2020

Stock Market Capitalization

Giant 0.00%
Large 0.00%
Medium 0.00%
Small 0.00%
Micro 0.00%
As of June 30, 2020

Stock Style Exposure

Large Cap Value --
Large Cap Blend --
Large Cap Growth --
Mid Cap Value --
Mid Cap Blend --
Mid Cap Growth --
Small Cap Value --
Small Cap Blend --
Small Cap Growth --
As of June 30, 2020
View More Holdings

Top 9 Holdings

Symbol Name % Weight Price % Chg
-- Nasdaq Biotechnology Index Swap Ubs Ag -78.78% -- --
-- Nasdaq Biotechnology Index Swap Bank Of America Na -54.88% -- --
-- Nasdaq Biotechnology Index Swap Societe Generale -30.65% -- --
-- Ishares Biotech (Ibb) Swap Morgan Stanley & Co. International Plc -15.62% -- --
-- Ishares Biotech (Ibb) Swap Bank Of America Na -6.61% -- --
-- Nasdaq Biotechnology Index Swap Citibank Na -3.90% -- --
-- United States Treasury Bills 3.55% -- --
-- Nasdaq Biotechnology Index Swap Morgan Stanley & Co. International Plc -1.31% -- --
-- Nasdaq Biotechnology Index Swap Credit Suisse International -1.21% -- --
As of June 30, 2020
Advertisement

Basic Info

Investment Strategy
The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style --
Fixed Income Style --
Broad Asset Class Alternative
Broad Category Alternative
Category Name Trading--Inverse Equity
Prospectus Objective Specialty - Technology
Fund Owner Firm Name ProShares
Benchmark Index
NASDAQ Biotechnology TR USD -200.0%
Reports
One Page Report Download

Manager Info

Name Tenure
Michael Neches 6.75 yrs
Tarak Davé 2.17 yrs

Net Fund Flows

1M 323040.0
3M 2.610M
6M -3.085M
YTD -3.085M
1Y 1.838M
3Y -14.16M
5Y -116.99M
10Y 78.77M
As of June 30, 2020

Risk Info

Beta (5Y) -2.197
Max Drawdown (All) 99.52%
Historical Sharpe Ratio (10Y) -0.8257
Historical Sortino (All) -1.450
30-Day Rolling Volatility 44.59%
Daily Value at Risk (VaR) 1% (All) 8.05%
Monthly Value at Risk (VaR) 1% (All) 26.68%

Fundamentals

Dividend Yield TTM (7-13-20) 3.08%
30-Day SEC Yield --
7-Day SEC Yield --
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio --
Weighted Average Price to Book Ratio --
Weighted Median ROE --
Weighted Median ROA --
Forecasted Dividend Yield --
Forecasted PE Ratio --
Forecasted Price to Sales Ratio --
Forecasted Price to Book Ratio --
Number of Holdings 18
As of June 30, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth --
Forecasted Book Value Growth --
Forecasted Cash Flow Growth --
Forecasted Earnings Growth --
Forecasted Revenue Growth --
As of June 30, 2020

Comparables

Edit

Attributes

Key Dates
Inception Date 4/6/2010
Termination Date
Last Annual Report Date 5/31/2019
Last Prospectus Date 10/1/2019
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund Yes
Inverse Fund Yes
Leveraged Fund Yes
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund Yes
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.